Spots Global Cancer Trial Database for Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Official Title: A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF

Study ID: NCT00910728

Conditions

Primary Myelofibrosis (PMF)

Post-Polycythaemia Vera

Essential Thrombocythaemia Myelofibrosis

Interventions

AZD1480

Study Description

Brief Summary: This study is being conducted to test study drug AZD1480 to see how it may work to treat myeloproliferative diseases. The main purpose of this study is to determine the safety and tolerability of AZD1480. This is the first time the drug has been given to humans and is classed as a first time in man study. Its main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. The study will also assess the blood levels and action of AZD1480 in the body over a period of time and will indicate whether the drug has a therapeutic effect on myeloproliferative diseases.

Detailed Description: